Adeno-associated virus (AAV) vectors have become an important tool for delivering therapeutic genes for a wide range of neurological diseases. AAV serotypes possess differential cellular tropism in the central nervous system. Although several AAV serotypes or mutants have been reported to transduce the brain efficiently, conflicting data occur across studies with the use of various rodent strains from different genetic backgrounds. Herein, we performed a systematic comparison of the brain transduction properties among five AAV serotypes (AAV2, 5, 7, 8, and 9) in two common rodent strains (C57BL/6J and FVB/N), following local intrastriatal injection of AAV vectors encoding enhanced green fluorescent protein (EGFP) driven by the CBh promoter. Important differences were found regarding overall cellular tropism and transduction efficiency, including contralateral transduction among the AAV serotypes and between the mouse strains. We have further found loss of NeuN-immunoreactivity and microglial activation from AAV transduction in the different mouse strains. The important strain-specific differences from our study suggest that the genetic background of the mouse may affect AAV serotype transduction properties in the brain. These data can provide valuable information about how to choose an effective AAV vector for clinical application and interpret the data obtained from preclinical studies and clinical trials.
Get full access to this article
View all access options for this article.
References
1.
AxelsenTM, WoldbyeDPD. Gene therapy for Parkinson's disease, An Update. J Parkinsons Dis, 2018; 8:195–215.
2.
HocquemillerM, GierschL, AudrainM, et al.Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther, 2016; 27:478–496.
3.
WildEJ, TabriziSJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol, 2017; 16:837–847.
4.
GrimmD, BuningH. Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum Gene Ther, 2017; 28:1075–1086.
5.
PillayS, MeyerNL, PuschnikAS, et al.An essential receptor for adeno-associated virus infection. Nature, 2016; 530:108–112.
6.
SummerfordC, BartlettJS, SamulskiRJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med, 1999; 5:78–82.
7.
AschauerDF, KreuzS, RumpelS. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One, 2013; 8:e76310.
8.
CearleyCN, WolfeJH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther, 2006; 13:528–537.
9.
KleinRL, DaytonRD, LeidenheimerNJ, et al.Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther, 2006; 13:517–527.
10.
TaymansJM, VandenbergheLH, HauteCV, et al.Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther, 2007; 18:195–206.
11.
HordeauxJ, WangQ, KatzN, et al.The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther, 2018; 26:664–668.
12.
HordeauxJ, YuanY, ClarkPM, et al.The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol Ther, 2019; 27:912–921.
13.
SuwanmaneeT, FerrisMT, HuP, et al.Toward personalized gene therapy: characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery. Mol Ther Methods Clin Dev, 2017; 5:83–92.
14.
Hacein-Bey-AbinaS, von KalleC, SchmidtM, et al.A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003; 348:255–256.
15.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
16.
MorganRA, YangJC, KitanoM, et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010; 18:843–851.
17.
TaketoM, SchroederAC, MobraatenLE, et al.FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A, 1991; 88:2065–2069.
BrownGC, NeherJJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci, 2014; 15:209–216.
21.
BradlM, LassmannH. Oligodendrocytes: biology and pathology. Acta Neuropathol, 2010; 119:37–53.
22.
BroekmanML, ComerLA, HymanBT, et al.Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience, 2006; 138:501–510.
23.
DodgeJC, ClarkeJ, SongA, et al.Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A, 2005; 102:17822–17827.
SomogyiP, BolamJP, SmithAD. Monosynaptic cortical input and local axon collaterals of identified striatonigral neurons. A light and electron microscopic study using the Golgi-peroxidase transport-degeneration procedure. J Comp Neurol, 1981; 195:567–584.
26.
Gusel'nikovaVV, KorzhevskiyDE. NeuN as a neuronal nuclear antigen and neuron differentiation marker. Acta Naturae, 2015; 7:42–47.
27.
DavoliMA, FourtounisJ, TamJ, et al.Immunohistochemical and biochemical assessment of caspase-3 activation and DNA fragmentation following transient focal ischemia in the rat. Neuroscience, 2002; 115:125–136.
28.
IgarashiT, HuangTT, NobleLJ. Regional vulnerability after traumatic brain injury: gender differences in mice that overexpress human copper, zinc superoxide dismutase. Exp Neurol, 2001; 172:332–341.
29.
McPhailLT, McBrideCB, McGrawJ, et al.Axotomy abolishes NeuN expression in facial but not rubrospinal neurons. Exp Neurol, 2004; 185:182–190.
30.
Unal-CevikI, KilinçM, Gürsoy-OzdemirY, et al.Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res, 2004; 1015:169–174.
31.
LindD, FrankenS, KapplerJ, et al.Characterization of the neuronal marker NeuN as a multiply phosphorylated antigen with discrete subcellular localization. J Neurosci Res, 2005; 79:295–302.
32.
MaxeinerS, GlassmannA, KaoHT, et al.The molecular basis of the specificity and cross-reactivity of the NeuN epitope of the neuron-specific splicing regulator, Rbfox3. Histochem Cell Biol, 2014; 141:43–55.
33.
WatakabeA, OhtsukaM, KinoshitaM, et al.Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res, 2015; 93:144–157.
34.
AlbertK, VoutilainenMH, DomanskyiA, et al.AAV vector-mediated gene delivery to substantia nigra dopamine neurons: implications for gene therapy and disease models. Genes (Basel), 2017; 8:E63.
35.
HowardDB, PowersK, WangY, et al.Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology, 2008; 372:24–34.
36.
SvenningssonP, NishiA, FisoneG, et al.DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol, 2004; 44:269–296.
37.
DangMT, YokoiF, YinHH, et al.Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc Natl Acad Sci U S A, 2006; 103:15254–15259.
38.
ReiniusB, BlunderM, BrettFM, et al.Conditional targeting of medium spiny neurons in the striatal matrix. Front Behav Neurosci, 2015; 9:71.
39.
DunhamNW, MiyaTS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc, 1957; 46:208–209.
40.
StertzL, MagalhaesPV, KapczinskiF. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry, 2013; 26:19–26.
41.
StreitWJ, MrakRE, GriffinWS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation, 2004; 1:14.
42.
KaurK, GillJS, BansalPK, et al.Neuroinflammation—a major cause for striatal dopaminergic degeneration in Parkinson's disease. J Neurol Sci, 2017; 381:308–314.
43.
LehmanEJ, KulnaneLS, GaoY, et al.Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet, 2003; 12:2949–2956.
44.
FrohlichC, PaarmannK, SteffenJ, et al.Genomic background-related activation of microglia and reduced beta-amyloidosis in a mouse model of Alzheimer's disease. Eur J Microbiol Immunol (Bp), 2013; 3:21–27.
